247 related articles for article (PubMed ID: 33535410)
1. Increased Alopecia Areata Risk in Children with Attention-Deficit/Hyperactivity Disorder and the Impact of Methylphenidate Use: A Nationwide Population-Based Cohort Study.
Ho HY; Wong CK; Wu SY; Hsiao RC; Chen YL; Yen CF
Int J Environ Res Public Health; 2021 Feb; 18(3):. PubMed ID: 33535410
[TBL] [Abstract][Full Text] [Related]
2. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
Shyu YC; Yuan SS; Lee SY; Yang CJ; Yang KC; Lee TL; Wang LJ
Schizophr Res; 2015 Oct; 168(1-2):161-7. PubMed ID: 26363968
[TBL] [Abstract][Full Text] [Related]
3. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study.
Liang SH; Yang YH; Kuo TY; Liao YT; Lin TC; Lee Y; McIntyre RS; Kelsen BA; Wang TN; Chen VC
Res Dev Disabil; 2018 Jan; 72():96-105. PubMed ID: 29121517
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder.
Chen VC; Yang YH; Yu Kuo T; Lu ML; Tseng WT; Hou TY; Yeh JY; Lee CT; Chen YL; Lee MJ; Dewey ME; Gossop M
Epidemiol Psychiatr Sci; 2020 Jul; 29():e146. PubMed ID: 32686635
[TBL] [Abstract][Full Text] [Related]
5. Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH.
Liu YC; Chen VC; Yang YH; Chen YL; Gossop M
Epidemiol Psychiatr Sci; 2021 Feb; 30():e14. PubMed ID: 33583471
[TBL] [Abstract][Full Text] [Related]
6. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
[No Abstract] [Full Text] [Related]
7. Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.
Liao YT; Yang YH; Kuo TY; Liang HY; Huang KY; Wang TN; Lee Y; McIntyre RS; Chen VC
Eur Child Adolesc Psychiatry; 2018 Mar; 27(3):279-288. PubMed ID: 28856464
[TBL] [Abstract][Full Text] [Related]
8. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
[TBL] [Abstract][Full Text] [Related]
9. Risk of Respiratory Infectious Diseases and the Role of Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder: A Population-Based Cohort Study.
Li DJ; Chen YL; Hsiao RC; Chen HL; Yen CF
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34071586
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Gau SS; Shen HY; Soong WT; Gau CS
J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
[TBL] [Abstract][Full Text] [Related]
12. Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
Wang LJ; Yang KC; Lee SY; Yang CJ; Huang TS; Lee TL; Yuan SS; Shyu YC
PLoS One; 2016; 11(8):e0161061. PubMed ID: 27518196
[TBL] [Abstract][Full Text] [Related]
13. The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder.
Golubchik P; Levy T; Weizman A
Int Clin Psychopharmacol; 2018 Nov; 33(6):330-333. PubMed ID: 29958238
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan.
Wang LJ; Shyu YC; Yuan SS; Yang CJ; Yang KC; Lee TL; Lee SY
J Psychiatr Res; 2016 Jan; 72():6-14. PubMed ID: 26519764
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
Liu Q; Zhang H; Fang Q; Qin L
J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
[TBL] [Abstract][Full Text] [Related]
16. Heart rate variability and methylphenidate in children with ADHD.
Buchhorn R; Conzelmann A; Willaschek C; Störk D; Taurines R; Renner TJ
Atten Defic Hyperact Disord; 2012 Jun; 4(2):85-91. PubMed ID: 22328340
[TBL] [Abstract][Full Text] [Related]
17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
[TBL] [Abstract][Full Text] [Related]
19. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
20. Reversible Alopecia Secondary to OROS Methylphenidate.
Núñez-Garces M; Sánchez-Gayango A; Romero-Pérez C
Rev Colomb Psiquiatr (Engl Ed); 2020; 49(3):208-210. PubMed ID: 32888666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
